Company Description

Crafton Biotech is a privately-held mRNA drug developer that is advancing a pipeline of novel vaccines and therapeutics powered by its proprietary platforms—PureCap®, a leading mRNA Cap2 analog enabling ultra-pure, GMP-grade mRNA with superior protein expression, and CRAFT™, which allows rapid, DNA-free mRNA synthesis with chemical modifications—with a COVID program entering the clinic in 2026 and additional discovery-stage assets in oncology and beyond.